CN105749091A - 一种用于治疗缺血性心脏病心肌梗死的药物 - Google Patents
一种用于治疗缺血性心脏病心肌梗死的药物 Download PDFInfo
- Publication number
- CN105749091A CN105749091A CN201610099475.XA CN201610099475A CN105749091A CN 105749091 A CN105749091 A CN 105749091A CN 201610099475 A CN201610099475 A CN 201610099475A CN 105749091 A CN105749091 A CN 105749091A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- myocardial infarction
- ischemic heart
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 19
- 208000031225 myocardial ischemia Diseases 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title description 4
- 241000208340 Araliaceae Species 0.000 claims abstract description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 20
- 241000921449 Rhodobryum roseum Species 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 4
- 230000000302 ischemic effect Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241001232328 Heterotheca Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 abstract 2
- 235000005492 Artemisia desertorum Nutrition 0.000 abstract 2
- 241001661344 Artemisia desertorum Species 0.000 abstract 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 2
- 241000994756 Codoriocalyx motorius Species 0.000 abstract 2
- 235000017803 cinnamon Nutrition 0.000 abstract 2
- 244000181485 fuzzy flat sedge Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010061876 Obstruction Diseases 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 150000002823 nitrates Chemical class 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 230000001709 ictal effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010007513 Cardiac aneurysm Diseases 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010027727 Mitral valve incompetence Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000005907 mitral valve insufficiency Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗缺血性心脏病心肌梗死的药物,它是由以下重量配比的原料药材制备而成:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份。本发明运用:毛轴莎草性温归肾,活血散瘀、利水消肿;山茱萸酸涩性温,补益肝肾,涩精固脱;舞草安神,镇静,祛瘀生新,活血;回心草安神镇静、镇心悸;沙漠嘎祛痰,平喘,解表;山柰行气温中;个参、人参大补元气,温补真阳。桂枝、甘草温阳化气,振奋心阳。诸药合用,共奏补益阳气、个温振心阳之功。临床实验证明,本发明能够安全有效治疗缺血性心脏病心肌梗死。
Description
技术领域
本发明涉及一种中药,具体涉及一种用于治疗缺血性心脏病心肌梗死的药物。
背景技术
缺血性心脏病心肌梗死是指由于长期心肌缺血导致心肌局限性或弥漫性纤维化,从而产生心脏收缩和(或)舒张功能受损,引起心脏扩大或僵硬、充血性心力衰竭、心律失常等一系列临床表现的临床综合征。这类心肌病大多是由于冠状动脉多支病变,甚至是弥漫性病变引起的心肌广泛缺血、变性、坏死和纤维化,另外还掺杂有心肌顿抑和冬眠心肌,从而导致严重心肌功能失常、心脏呈球形扩大和(或)心力衰竭。缺血性心脏病包括粥样硬化病变引致的冠状动脉梗阻或狭窄。心肌缺血引致的左心室室壁瘤,心肌栓塞后心室间隔缺损和乳头肌缺血引起的二尖瓣关闭不全,是中老年常见多发的后天性心脏病。
中医称之为“胸痹心痛”,胸痹心痛是由于正气亏虚,饮食、情志、寒邪等所引起的以痰浊、瘀血、气滞、寒凝痹阻心脉,以膻中或左胸部发作性憋闷、疼痛为主要临表现的一种病证。轻者偶发短暂轻微的胸部沉闷或隐痛,或为发作性膻中或左胸含糊不清的不适感;重者疼痛剧烈,或呈压榨样绞痛。常伴有心悸,气短,呼吸不畅,甚至喘促,惊恐不安,面色苍白,冷汗自出等。多由劳累、饱餐、寒冷及情绪激动而诱发,亦可无明显诱因或安静时发病。
临床表现
多发于40岁以上的中老年人,胸痹心痛以胸骨后或心前区发作性闷痛为主,亦可表现为灼痛、绞痛、刺痛或隐痛、含糊不清的剧痛向左肩背沿手少阴心经循行部位放射等不适感,持续时间短暂,多为数秒钟至15分钟之内。若疼痛剧烈,持续时间长达30分钟以上,休息或服药后仍不能缓解,伴有面色苍白,汗出,肢冷,脉结代,甚至旦发夕死,夕发旦死,为真心痛的证候特征。常由情志刺激、饮食过饱、感受寒冷、劳倦过度而诱发,亦可在安静时或夜间无明显诱因而发病。多伴有短气乏力,自汗心悸,甚至喘促,脉结代。多数患者休息或除去诱因后症状可以缓解。
诊断上主要依靠实验室检查①X线胸片:有肺间质水肿、肺淤血及胸腔积液心脏多不大,也无心腔扩张。有时可见冠状动脉和主动脉钙化。②心电图:可表现为各种心律失常,窦性心动过速,房早、房颤、室性心律失常及传导阻滞等。③超声心动图:常表现为舒张受限心室肌呈普遍性轻度收缩力减弱,无室壁瘤局部室壁运动障碍。无二尖瓣反流。④心导管:即使在肺水肿消退后,仍表现为左室舒张末压轻度增高舒张末期容量增加和左室射血分数轻度减少。⑤冠状动脉造影:常有2支以上的弥漫性血管病变。
药物治疗①降脂药物,降低血清胆固醇药物,如洛伐他丁、氯贝丁酯、考来烯胺等。②改善心肌缺血对于有心绞痛发作或心电图有缺血改变而血压无明显降低者,可考虑应用血管扩张药改善心肌缺血,硝酸甘油和硝酸异山梨酯。硝酸甘油因存在“首过效应”故采取舌下含服方法;硝酸异山梨酯为速效长效硝酸制剂,采取口服、舌下含服、口腔喷雾亦可。③钙通道拮抗药:治疗心绞痛是通过降低心肌耗氧量、改善心肌缺血区的血流灌注和抑制血小板聚集来实现的,如硝苯地平。④冠状动脉扩张剂,能扩张冠状动脉的血管扩张剂,从理论上说将能增加冠状动脉的血流,改善心肌的血供,缓解心绞痛。但由于冠心病时冠状动脉病变情况复杂,有些血管扩张剂如双嘧达莫,可能扩张无病变或轻度病变的动脉较扩张重度病变的动脉远为显著,减少侧支循环的血流量,引起所谓“冠状动脉窃血”,增加了正常心肌的供血量,使缺血心肌的供血量反而更减少,故不主张适用。④中药治疗缺血性心脏病心肌梗死可用中医中药治疗,效果比较理想。同时应注意饮食以及生活习惯。
本发明所涉及药材均可见记载于《中华本草》。
发明内容
本发明旨在提供一种用于治疗缺血性心脏病心肌梗死的药物,通过选择合适的药材及其配比,达到安全有效治愈缺血性心脏病心肌梗死的目的。
为了达到上述目的,本发明采用以下技术方案:
一种用于治疗缺血性心脏病心肌梗死的药物,其特征在于,它是由以下重量配比的原料药材制备而成:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份。
下面结合中药学理论说明本发明有益效果:
发明人认为,胸痹心痛的病机关键在于外感或内伤引起心脉痹阻,其病位在心,但与肝、脾、肾三脏功能的失调有密切的关系。因心主血脉的正常功能,有赖于肝主疏泄,脾主运化,肾藏精主水等功能正常。其病性有虚实两方面,常常为本虚标实,虚实夹杂,虚者多见气虚、阳虚、阴虚、血虚,尤以气虚、阳虚多见;实者不外气滞、寒凝、痰浊、血瘀,并可交互为患,其中又以血瘀、痰浊多见。针对本病本虚标实,虚实夹杂,发作期以标实为主,缓解期以本虚为主的病机特点,其治疗应补其不足,泻其有余,主要以辛温通阳或温补阳气为治疗大法。
本发明运用:毛轴莎草性温归肾,活血散瘀、利水消肿;山茱萸酸涩性温,补益肝肾,涩精固脱;舞草安神,镇静,祛瘀生新,活血;回心草安神镇静、镇心悸;沙漠嘎祛痰,平喘,解表;山柰行气温中;个参、人参大补元气,温补真阳。桂枝、甘草温阳化气,振奋心阳。诸药合用,共奏补益阳气、个温振心阳之功。
下面结合临床实验数据说明本发明的有益效果:
1、一般资料
发明人2012年5月-2013年5月间共收集60例缺血性心脏病心肌梗死患者。随机分为:治疗组30例,对照组30例。其中治疗组男11例、女19例,年龄42~66岁;对照组男12例、女18例,年龄48~69岁。两组性别、年龄、病程等资料无显著性差异,具有可比性。
诊断标准
①左侧胸膺或膻中处突发憋闷而痛,疼痛性质为灼痛、绞痛、刺痛或隐痛、含糊不清的不适感等,疼痛常可窜及肩背、前臂、咽喉、胃脘部等,甚者可卅手少阴、手厥阴经循行部位窜至中指或小指,常兼心悸。
②突然发病,时作时止,反复发作。持续时间短暂,一般几秒至数十分钟,经休息或服药后可迅速缓解。
③多见于中年以上,常因情志波动,气候变化,多饮暴食,劳累过度等而诱发。亦有无明显诱因或安静时发病者。
④心电图应列为必备的常规检查,必要时可作动态心电图、标测心电图和心功能测定、运动试验心电图。休息时心电图明显心肌缺血,心电图运动试验阳性,有助于诊断。
⑤若疼痛剧烈,持续时间长,达30分钟以上,含化硝酸甘油片后难以缓解,可见汗出肢冷,面色苍白,唇甲青紫,手足青冷至肘膝关节处,甚至旦发夕死、夕发旦死,相当于急性心肌梗死,常合并心律失常、心功能不全及休克,多为真心痛表现,应配合心电图动态观察及血清酶学、白细胞总数、血沉等检查,以进一步明确诊断。
纳入标准除有典型心绞痛等症状外,心电图均有ST段水平下移或T波改变,年龄在18~70岁之间,性别不限。
排除标准①活动性心肌炎、肥厚性心脏梗死病史;②不稳定性心绞痛或过去两个月内有急性心机梗死病史;③未控制的心律失常,包括病态窦房结综合征或Ⅱ型以上房室传导阻滞;④妊娠或哺乳妇女;⑤收缩压<85mmhg或>180mmhg,舒张压>110mmhg;⑥有明显肝、肾功能损害。
2、治疗方法
治疗组口服本发明按照具体实施例3制得的胶囊,每日3次。治疗1个月。
对照组口服单硝酸异山梨酯片,一次20mg,一日2次。治疗1个月。
3、疗效标准与治疗结果
3.1疗效标准
①痊愈:治疗后胸痛、胸闷、心悸、气短等症状完全缓解,心绞痛分级降低2级,心电图恢复正常或运动试验由阳性转阴或大致正常。原I、Ⅱ级者心绞痛基本消失,即在较重的超过日常活动的体力活动时,也基本不出现心绞痛,不需服用硝酸盐类药物者;
②有效:治疗后胸痛、胸闷、心悸、气短等症状明显缓解,心绞痛分级降低1级,ST段下降者经治疗后回升1.5mV以上,但未达正常范围,或T波由平坦转为直立。原I级者心绞痛基本消失,硝酸盐类药物减用一半以上者;
③无效:治疗后胸痛、胸闷、心悸、气短等症状无明显改善,心电图与治疗前基本相同,或ST段叫治疗前下降0.5mV以上,主要导联T波倒置加深75%以上或直立T波转变为平坦,或平坦T波转为倒置。心绞痛和硝酸盐类药物用量无改变或有所减少但未达到有效程度者。
④加重:治疗后临床症状加重,心绞痛发作次数、程度及持续时间增剧硝酸盐类药物,用量增加者。
3.2治疗统计结果见表1。
表1两组疗效比较
可见,本发明制得的药物能够安全有效治疗缺血性心脏病心肌梗死,治愈率高。
具体实施方式
为了更好地理解和实施本发明,下面结合具体实施例进一步说明本发明。
实施例1
称取:毛轴莎草9克、山茱萸8克、舞草15克、回心草9克、沙漠嘎3克、山柰6克、个参12克、人参6克、桂枝8克、甘草3克;加8倍量水,煎煮1.5小时,过滤;滤渣加6倍量水,煎煮1小时,过滤;合并滤液,浓缩至120克,即得符合正常成人一天用量的煎剂。
用于治疗缺血性心脏病心肌梗死。口服,每日服用一次。
实施例2
称取:毛轴莎草9克、山茱萸8克、舞草15克、回心草9克、沙漠嘎3克、山柰6克、个参12克、人参6克、桂枝8克、甘草3克;加10倍量水,煎煮2小时,过滤;滤渣加8倍量水,煎煮1.5小时,过滤;合并滤液,浓缩,干燥,包装,即得符合正常成人一天用量的散剂。
用于治疗缺血性心脏病心肌梗死。口服,每日分早晚两次服用。
实施例3
称取:毛轴莎草9克、山茱萸8克、舞草15克、回心草9克、沙漠嘎3克、山柰6克、个参12克、人参6克、桂枝8克、甘草3克;加6倍量水,煎煮3次,每次煎煮1小时,合并煎煮液,浓缩,干燥,装入胶囊壳,即得符合正常成人一天用量的胶囊剂。
用于治疗缺血性心脏病心肌梗死。口服,每日分早中晚三次服用。
Claims (4)
1.一种用于治疗缺血性心脏病心肌梗死的药物,其特征在于,它是由以下重量配比的原料药材制备而成:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份。
2.如权利要求1所述的用于治疗缺血性心脏病心肌梗死的药物,其特征在于,其制备方法为:称取:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份;加8倍量水,煎煮1.5小时,过滤;滤渣加6倍量水,煎煮1小时,过滤;合并滤液,浓缩至120份,即得煎剂;上述份均是指重量份。
3.如权利要求1所述的用于治疗缺血性心脏病心肌梗死的药物,其特征在于,其制备方法为:称取:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份;加10倍量水,煎煮2小时,过滤;滤渣加8倍量水,煎煮1.5小时,过滤;合并滤液,浓缩,干燥,包装,即得散剂;上述份均是指重量份。
4.如权利要求1所述的用于治疗缺血性心脏病心肌梗死的药物,其特征在于,其制备方法为:称取:毛轴莎草9份、山茱萸8份、舞草15份、回心草9份、沙漠嘎3份、山柰6份、个参12份、人参6份、桂枝8份、甘草3份;加6倍量水,煎煮3次,每次煎煮1小时,合并煎煮液,浓缩,干燥,装入胶囊壳,即得胶囊剂;上述份均是指重量份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610099475.XA CN105749091A (zh) | 2016-02-23 | 2016-02-23 | 一种用于治疗缺血性心脏病心肌梗死的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610099475.XA CN105749091A (zh) | 2016-02-23 | 2016-02-23 | 一种用于治疗缺血性心脏病心肌梗死的药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105749091A true CN105749091A (zh) | 2016-07-13 |
Family
ID=56330245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610099475.XA Pending CN105749091A (zh) | 2016-02-23 | 2016-02-23 | 一种用于治疗缺血性心脏病心肌梗死的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105749091A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027468A (zh) * | 2014-06-24 | 2014-09-10 | 俞天阳 | 一种用于治疗头皮脂溢性皮炎的中药 |
CN104940597A (zh) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗心肌梗死的中药组合物及其制备方法 |
-
2016
- 2016-02-23 CN CN201610099475.XA patent/CN105749091A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027468A (zh) * | 2014-06-24 | 2014-09-10 | 俞天阳 | 一种用于治疗头皮脂溢性皮炎的中药 |
CN104940597A (zh) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗心肌梗死的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1209121C (zh) | 一种治疗心脏病的强心通脉液及其制备方法 | |
CN101991816B (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN102078510B (zh) | 治疗冠心病的中药组合物 | |
CN103202879B (zh) | 一种治疗慢性心力衰竭的中药组合物及制备方法 | |
CN104069446A (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN103230457B (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法与用途 | |
CN103007192B (zh) | 一种治疗胸痹的中药组合物 | |
CN102580030B (zh) | 具有降血糖功效的外用中药组合物、制剂及其制备方法 | |
CN102430085B (zh) | 一种治疗冠心病的中药 | |
CN104906274A (zh) | 治疗冠心病的中药 | |
CN105749091A (zh) | 一种用于治疗缺血性心脏病心肌梗死的药物 | |
CN110882347A (zh) | 一种治疗心血管疾病的中药组合物 | |
CN110339323A (zh) | 一种治疗心动过缓的中药组合物及其制备方法和应用 | |
CN100459990C (zh) | 一种治疗冠心病的药物及其制备方法 | |
CN114848775B (zh) | 一种治疗急性期心肌梗死的中药组合物及其中药制剂和应用 | |
CN102908580A (zh) | 一种治疗妇女血崩的中药组合物及其制备方法 | |
CN103028094A (zh) | 一种治疗冠心病的中成药 | |
CN106606744A (zh) | 一种用于治疗ⅱ型糖尿病的组合药物 | |
CN106620253A (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
CN106177422A (zh) | 一种温阳散寒的中药配方 | |
CN105168653A (zh) | 一种用于治疗冠心病的中药组合物 | |
CN106237069A (zh) | 一种治疗冠心病的中药配方 | |
CN105582280A (zh) | 一种治疗冠心病心绞痛的中药制剂 | |
CN105596528A (zh) | 一种用于治疗心脏神经症的药物 | |
CN105560835A (zh) | 一种用于治疗慢性充血性心力衰竭的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160713 |
|
WD01 | Invention patent application deemed withdrawn after publication |